Am J Transplant, Volume 20, Suppl 3 Archives - ATC Abstracts

2020 American Transplant Congress
Profiling Non-HLA Antibodies in Antibody-Mediated Rejection Following Cardiac Transplantation
S. B. See¹, B. S. Mantell², K. J. Clerkin³, B. Ray⁴, E. R. Vasilescu⁵, C. Marboe⁵, Y. Naka⁶, S. Restaino³, P. C. Colombo³, L. Addonizio², M. A. Farr³, E. Zorn¹
¹Columbia Center for Translational Immunology, Columbia University Irving Medical Center, New York, NY, ²Department of Pediatrics, Columbia University Irving Medical Center, New York, NY, ³Department of Medicine, Columbia University Irving Medical Center, New York, NY, ⁴Research and Development, Immucor, Waukesha, WI, ⁵Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY, ⁶Department of Surgery, Columbia University Irving Medical Center, New York, NY
*Purpose: Antibody-mediated rejection (AMR) driven by the development of donor-specific antibodies (DSA) directed against mismatched donor HLA is a major risk factor for graft loss…
2020 American Transplant Congress
CD4+ T-Cells Express High Levels of Messenger RNA Coding for Heparanase in Cultures with Matrigel
N. Chai, G. Wu, I. Kim, S. Jordan, A. Klein, T. Brennan
Cedars-Sinai Med Ctr, Los Angeles, CA
*Purpose: Heparanase (Hpse) is the sole heparan sulfate (HS) degrading enzyme regulating multiple biological activities that enhance immune cell migration, blood vessel growth and cell…
2020 American Transplant Congress
Everolimus-Treatment Inhibits the Transition of the Immature Subsets of Liver Natural Killer Cells to Mature State and Enhances Anti-Tumor Activity
Y. Tanaka, J. Saparbay, H. Ohdan
Gastreenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan
*Purpose: The immunosuppressive regimen currently used after organ transplantation efficiently reduces the adaptive immune components. During suppressed adaptive immunity, the innate immune cells may play…
2020 American Transplant Congress
HLA Molecular Mismatch Analysis in Recipients of Kidney Plus Hematopoietic Stem/Facilitating Cell Transplant Tolerance Induction Protocol
C. Garcia-Sanchez¹, V. Kosmoliaptsis², H. Copley², J. Leventhal¹, S. Ildstad³
¹NU, Chicago, IL, ²Cambridge, Cambridge, United Kingdom, ³U of Louisville, Lousville, KY
*Purpose: To evaluate the potential role of HLA molecular mismatch (MM) analysis in predicting outcomes in a cohort of HLA-mismatched, related and unrelated recipients of…
2020 American Transplant Congress
Belatacept Monthly Therapy: Transplant Recipients’ Experience
S. N. Little¹, É. N. Arsenault Knudsen², D. A. Mandelbrot¹
¹Transplant, University of Wisconsin Hospital and Clinics, Madison, WI, ²University of Wisconsin Hospital and Clinics, Madison, WI
*Purpose: While graft and patient outcomes with belatacept have been relatively well documented, the decision to use belatacept for kidney transplant recipients rests in part…
2020 American Transplant Congress
A Multicenter, Randomized, Controlled Trial to Steer Immunosuppressive Therapy by Virus-Specific T Cells after Pediatric Kidney Transplantation (IVIST-Trial)
T. Ahlenstiel-Grunow¹, A. Großhennig¹, R. Schild², J. Oh², C. Taylan³, L. Weber³, H. Staude⁴, M. Verboom¹, C. Schröder¹, R. Sabau¹, A. Koch¹, X. Liu¹, L. Pape¹
¹Hannover Medical School, Hannover, Germany, ²University Hospital Hamburg-Eppendorf, Hamburg, Germany, ³University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany, ⁴University Hospital of Rostock, Rostock, Germany
*Purpose: Pharmakokinetic monitoring of immunosuppressants alone is insufficient to estimate the individual intensity of immunosuppression after kidney transplantation (Tx). Virus-specific T cells (Tvis) correlate with…
2020 American Transplant Congress
Single-Dose Anti-Thymocyte Globulin is Non-Inferior to Divided-Dose for Induction Therapy in Kidney and Pancreas Transplantation
A. I. Ingemi¹, O. F. Bangash¹, S. McCoy¹, L. Hulse², J. Colonna¹, H. Sadr¹, S. Sutton¹, M. Coleman¹, T. Wilson¹, T. R. McCune¹
¹Sentara Norfolk General Hospital, Norfolk, VA, ²Children's Hospital of the King's Daughters, Norfolk, VA
*Purpose: Emerging studies suggest that single-dose rabbit antithymocyte globulin (rATG) is not inferior to the divided-dose, however this dosing strategy has never been evaluated in…
2020 American Transplant Congress
Novel Treatment of Acute Antibody-Mediated Rejection in a Nonhuman Primate Model of Kidney Allotransplantation
R. Schmitz¹, Z. W. Fitch¹, A. Y. Choi¹, M. Manook¹, J. Yoon¹, J. D. Lambris², J. Kwun¹, S. J. Knechtle¹
¹Department of Surgery, Duke University Medical Center, Durham, NC, ²Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA
*Purpose: One third of sensitized, HLA-incompatible transplant recipients experience acute antibody mediated rejection (AMR) with limited treatment options. We tested a novel treatment strategy for…
2020 American Transplant Congress
Quantifying Gender-Based Disparties in Liver Allocation: A Path Forward
B. A. Shelton¹, K. Olthoff², E. Pomfret³, K. A. Forde², D. Sawinski⁴, M. Gray¹, N. Ascher⁵, J. E. Locke¹
¹University of Alabama at Birmingham, Birmingham, AL, ²University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ³University of Colorado School of Medicine, Denver, CO, ⁴University of Pennsylvania, Philadelphia, PA, ⁵University of California at San Francisco School of Medicine, San Francisco, CA
*Purpose: Differences in local organ supply and demand have introduced geographic inequities in the Model for End-stage Liver Disease (MELD) based liver allocation system prompting…
2020 American Transplant Congress
Outcomes Following Resection of Mixed Hepatocellular-Cholangiocarcinoma, Hepatocellular Carcinoma, and Intrahepatic Cholangiocarcinoma: A Matched Analysis
M. L. Holzner¹, F. Parvin-Nejad², K. Fei³, S. Florman¹, M. E. Schwartz¹, P. Tabrizian¹
¹Recanati/Miller Transplantation Institute, Icahn School of Medicine at Mount Sinai, New York, NY, ²Icahn School of Medicine at Mount Sinai, New York, NY, ³Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY
*Purpose: Mixed hepatocellular-cholangiocarcinoma (HCC-CC) is a biphenotypic liver cancer thought to have unfavorable tumor biology and a poor prognosis. Surgical outcomes of HCC-CC remain unclear.…

1
2
3
…
223
Next Page »